Literature DB >> 25572957

Challenges in the Understanding and Treatment of Amyotrophic Lateral Sclerosis/Motor Neuron Disease.

Jeffrey Rosenfeld1, Michael J Strong.   

Abstract

With the acceleration in our understanding of ALS and the related motor neuron disease has come even greater challenges in reconciling all of the proposed pathogenic mechanisms and how this will translate into impactful treatments. Fundamental issues such as diagnostic definition(s) of the disease spectrum, relevant biomarkers, the impact of multiple novel genetic mutations and the significant effect of symptomatic treatments on disease progression are all areas of active investigation. In this review, we will focus on these key issues and highlight the challenges that confront both clinicians and basic science researchers.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25572957      PMCID: PMC4404444          DOI: 10.1007/s13311-014-0332-8

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN: 1878-7479            Impact factor:   7.620


  128 in total

Review 1.  Cognitive impairment, frontotemporal dementia, and the motor neuron diseases.

Authors:  Michael J Strong; Catherine Lomen-Hoerth; Richard J Caselli; Eileen H Bigio; Wencheng Yang
Journal:  Ann Neurol       Date:  2003       Impact factor: 10.422

Review 2.  The epidemiology of ALS: a conspiracy of genes, environment and time.

Authors:  Ammar Al-Chalabi; Orla Hardiman
Journal:  Nat Rev Neurol       Date:  2013-10-15       Impact factor: 42.937

3.  Minor cognitive disturbances in X-linked spinal and bulbar muscular atrophy, Kennedy's disease.

Authors:  Elisabeth Kasper; Martin Wegrzyn; Ivo Marx; Christin Korp; Wolfram Kress; Reiner Benecke; Stefan J Teipel; Johannes Prudlo
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2013-11-08       Impact factor: 4.092

4.  A study comparing patients with amyotrophic lateral sclerosis and their caregivers on measures of quality of life, depression, and their attitudes toward treatment options.

Authors:  Marilyn Trail; Naomi D Nelson; John N Van; Stanley H Appel; Eugene C Lai
Journal:  J Neurol Sci       Date:  2003-05-15       Impact factor: 3.181

5.  Percutaneous gastrojejunostomy in amyotrophic lateral sclerosis.

Authors:  M J Strong; A Rowe; R N Rankin
Journal:  J Neurol Sci       Date:  1999-10-31       Impact factor: 3.181

Review 6.  The genetics and neuropathology of amyotrophic lateral sclerosis.

Authors:  Ammar Al-Chalabi; Ashley Jones; Claire Troakes; Andrew King; Safa Al-Sarraj; Leonard H van den Berg
Journal:  Acta Neuropathol       Date:  2012-08-02       Impact factor: 17.088

7.  Early symptom progression rate is related to ALS outcome: a prospective population-based study.

Authors:  A Chiò; G Mora; M Leone; L Mazzini; D Cocito; M T Giordana; E Bottacchi; R Mutani
Journal:  Neurology       Date:  2002-07-09       Impact factor: 9.910

Review 8.  The evidence for altered RNA metabolism in amyotrophic lateral sclerosis (ALS).

Authors:  Michael J Strong
Journal:  J Neurol Sci       Date:  2009-10-18       Impact factor: 3.181

9.  Behavior matters--cognitive predictors of survival in amyotrophic lateral sclerosis.

Authors:  William T Hu; Matthew Shelnutt; Ashley Wilson; Nicole Yarab; Crystal Kelly; Murray Grossman; David J Libon; Jaffar Khan; James J Lah; Allan I Levey; Jonathan Glass
Journal:  PLoS One       Date:  2013-02-27       Impact factor: 3.240

10.  The cognitive and behavioural profile of amyotrophic lateral sclerosis: application of the consensus criteria.

Authors:  Monica Consonni; Sandro Iannaccone; Chiara Cerami; Paola Frasson; Marco Lacerenza; Christian Lunetta; Massimo Corbo; Stefano F Cappa
Journal:  Behav Neurol       Date:  2013       Impact factor: 3.342

View more
  8 in total

1.  The Spectrum of Motor Neuron Diseases: From Childhood Spinal Muscular Atrophy to Adult Amyotrophic Lateral Sclerosis.

Authors:  Stacey A Sakowski; Eva L Feldman
Journal:  Neurotherapeutics       Date:  2015-04       Impact factor: 7.620

Review 2.  Motor Neuron Gene Therapy: Lessons from Spinal Muscular Atrophy for Amyotrophic Lateral Sclerosis.

Authors:  Andrew P Tosolini; James N Sleigh
Journal:  Front Mol Neurosci       Date:  2017-12-07       Impact factor: 5.639

3.  Small GSK-3 Inhibitor Shows Efficacy in a Motor Neuron Disease Murine Model Modulating Autophagy.

Authors:  Estefanía de Munck; Valle Palomo; Emma Muñoz-Sáez; Daniel I Perez; Begoña Gómez-Miguel; M Teresa Solas; Carmen Gil; Ana Martínez; Rosa M Arahuetes
Journal:  PLoS One       Date:  2016-09-15       Impact factor: 3.240

4.  Discovery of Tirasemtiv, the First Direct Fast Skeletal Muscle Troponin Activator.

Authors:  Scott E Collibee; Gustave Bergnes; Alexander Muci; William F Browne; Marc Garard; Aaron C Hinken; Alan J Russell; Ion Suehiro; James Hartman; Raja Kawas; Pu-Ping Lu; Kenneth H Lee; David Marquez; Matthew Tomlinson; Donghong Xu; Adam Kennedy; Darren Hwee; Julia Schaletzky; Kwan Leung; Fady I Malik; David J Morgans; Bradley P Morgan
Journal:  ACS Med Chem Lett       Date:  2018-02-13       Impact factor: 4.345

5.  Nuclear poly(ADP-ribose) activity is a therapeutic target in amyotrophic lateral sclerosis.

Authors:  L McGurk; J Mojsilovic-Petrovic; V M Van Deerlin; J Shorter; R G Kalb; V M Lee; J Q Trojanowski; E B Lee; N M Bonini
Journal:  Acta Neuropathol Commun       Date:  2018-08-29       Impact factor: 7.801

Review 6.  Advances in nanotechnology-based strategies for the treatments of amyotrophic lateral sclerosis.

Authors:  G Y Wang; S L Rayner; R Chung; B Y Shi; X J Liang
Journal:  Mater Today Bio       Date:  2020-05-04

7.  Structural magnetic resonance imaging findings and histopathological correlations in motor neuron diseases-A systematic review and meta-analysis.

Authors:  Charlotte Zejlon; Dominik Nakhostin; Sebastian Winklhofer; Athina Pangalu; Zsolt Kulcsar; Sebastian Lewandowski; Johannes Finnsson; Fredrik Piehl; Caroline Ingre; Tobias Granberg; Benjamin Victor Ineichen
Journal:  Front Neurol       Date:  2022-08-30       Impact factor: 4.086

8.  Combinatory Biomarker Use of Cortical Thickness, MUNIX, and ALSFRS-R at Baseline and in Longitudinal Courses of Individual Patients With Amyotrophic Lateral Sclerosis.

Authors:  Anna M Wirth; Andrei Khomenko; Dobri Baldaranov; Ines Kobor; Ohnmar Hsam; Thomas Grimm; Siw Johannesen; Tim-Henrik Bruun; Wilhelm Schulte-Mattler; Mark W Greenlee; Ulrich Bogdahn
Journal:  Front Neurol       Date:  2018-07-30       Impact factor: 4.003

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.